CAPhO Connections Podcast

About CAPhO Connections Podcast

CAPhO Connections Podcast Series keeps the oncology pharmacy community informed on matters affecting you and updated on CAPhO’s news related to education, awards, advocacy and research. Whether it’s your morning commute to work, a walk in the park, or just relaxing at home, the CAPhO Connections Podcast will offer a convenient way to keep up to date with all things oncology pharmacy!

Publisher

Canadian Association of Pharmacy in Oncology

Category

education

Language

en

Explicit

No

First episode

25 May 2022

Latest episode

18 Sept 2026

Latest episodes

34 episodes in the feed.

1. 

   18 Sept 2026

   CAPhO Connections Podcast: Targeting Active RAS in Pancreatic Cancer: Daraxonrasib from Molecular Glue to Clinical Data

   Pancreatic cancer has long remained one of the most challenging malignancies to treat. Could pan-RAS inhibition reshape the future treatment landscape for pancreatic cancer? In this episode, we explore daraxonrasib, a first-in-class oral pan-RAS inhibitor that uses a novel molecular glue mechanism to target active RAS signaling. We'll review the landmark RASolute 302 trial, unpacking the key efficacy and safety findings and discussing what they may mean for the future of pancreatic cancer treatment. The conversation also examines where daraxonrasib may fit within the evolving treatment paradigm, including patient selection, treatment sequencing, and practical considerations for safe use such as toxicity management, drug interactions, monitoring, administration, and patient counselling. Finally, we'll explore the opportunities and challenges of integrating this emerging therapy into multidisciplinary pancreatic cancer care, including feasibility, supportive care, access, reimbursement, and future directions. Join us as we unpack the science, evidence, and clinical questions surrounding one of the most closely watched emerging therapies in pancreatic cancer! Learning Objectives: Describe the mechanism of action of Daraxonrasib as a first-in-class pan-RAS inhibitor and explain how it differs from conventional systemic therapies used in pancreatic cancer Review the landmark RASolute 302 trial, including its key efficacy and safety findings, and interpret the clinical significance of the study outcomes Discuss the evolving role of daraxonrasib within the pancreatic cancer treatment landscape, including potential patient selection and treatment sequencing across lines of therapy Recognize practical considerations for the safe use of daraxonrasib, including adverse event management, drug interactions, monitoring, administration, and patient counselling Explore the opportunities and challenges associated with integrating daraxonrasib into multidisciplinary pancreatic cancer care, including supportive care, access and reimbursement considerations, and future directions for clinical practice About the Guest: Ming-Hei Tai (https://www.linkedin.com/in/ming-hei-tai-pharmd-bcop-73349a179/) Ming-Hei Tai is currently an oncology pharmacist at William Beaumont University Hospital in Royal Oak, Michigan. He graduated from the University of Michigan Pharmacy School in 2019 and is a member of HOPA’s Publications and Resources Committee. As a pharmacist, he is involved in treating patients with both solid and liquid tumors, and has his own podcast, called PharmOncology (https://open.spotify.com/show/4Zh6KrgtDbpzGPdE1DBkkq). Resources Used: 1. Wolpin, B. M., Wainberg, Z. A., Garrido-Laguna, I., Manji, G. A., Spira, A. I., Azad, N. S., ... & O'Reilly, E. M. (2025). Trial in progress: RASolute 302—A phase 3, multicenter, global, open-label, randomized study of daraxonrasib (RMC-6236), a RAS (ON) multi-selective inhibitor, versus standard of care chemotherapy in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC). 2. Seufferlein, T., Hammel, P., Pietrantonio, F., Azad, N. S., Ko, A. H., Morizane, C., ... & Pant, S. Trial in Progress–RASolute 303: A Phase 3 Global, Open-Label, Randomized 3-Arm Study of Daraxonrasib Monotherapy or Daraxonrasib Plus Gemcitabine and Nab-paclitaxel Versus Gemcitabine and Nab-paclitaxel as a First Line Treatment for Patients With Metastatic Pancreatic Adenocarcinoma. 3. Honda, R. (2026). Daraxonrasib and Beyond: Pan‐RAS Inhibition, Resistance, and Next‐Generation Strategies. Cancer Science.

2. 

   17 Aug 2026

   CAPhO Connections Podcast: Liquid Clues: Decoding circulating tumor DNA (ctDNA) to Rewriting Colorectal Cancer Care

   This episode explores the evolving role of circulating tumour DNA (ctDNA) in reshaping colorectal cancer care and how detection of tumour-derived DNA fragments in plasma is challenging traditional reliance on imaging, pathology, and CEA for assessing disease burden and recurrence risk. We unpack what ctDNA represents biologically, including its role in identifying minimal residual disease and emerging actionable alterations, as well as its strengths and limitations in clinical interpretation. The discussion highlights how ctDNA is already influencing practice, from early detection of recurrence risk shortly after surgery to guiding surveillance strategies and managing cases where ctDNA is positive despite negative imaging, raising important questions about how success is defined in curative-intent treatment and when to act on molecular signals. We also examine real-world barriers to feasible adoption, alongside the rise of early-onset colorectal cancer and shifting screening thresholds in Canada. Overall, the episode highlights an emerging era of precision oncology where multidisciplinary teams come together to turn ctDNA signals into earlier answers, clearer decisions, and more proactive cancer care. After this episode, listeners will be able to: Understand what ctDNA is and why it is transforming how we detect and define colorectal cancer recurrence earlier than ever before. Explore how ctDNA is reshaping real-world colorectal cancer care, from post-surgical surveillance to guiding treatment decisions alongside imaging and CEA. Examine how to interpret ctDNA results in practice, including discordant findings and what they mean for disease activity, risk, and treatment. Discuss the growing role of ctDNA in precision oncology, including actionable mutations, treatment adaptation, and minimal residual disease monitoring. Identify current barriers and future opportunities for ctDNA adoption, including turnaround time, access, cost, rising early-onset CRC, and multidisciplinary collaboration in advancing care. About the Author: Stacey Cohen Dr. Stacey A. Cohen is a Professor at the Fred Hutch Cancer Center and University of Washington. She is a GI medicaloncologist, with a clinical practice that focuses on lower GI cancers. She is the co-director of the Colorectal Cancer and Peritoneal Malignancy (HIPEC) multidisciplinary clinics. Her research focuses on biomarkers of prognosis and treatment response, with a special focus on circulating tumor DNA (ctDNA). Visit the CAPhO website for the list of resources used. (https://www.capho.org/resources/resource-library/capho-connections-podcast-liquid-clues-decoding-circulating-tumor-dna)

3. 

   30 Jul 2026

   CAPhO Connections Podcast: Pharmacy Technician Spotlight Series: RPhTs at the front line of oncology drug shortages: An Interview with Miranda Artiga

   Oncology medicines are increasingly implicated in National drug shortages, which could result in a crisis for treatment of patients who need the drug. After this episode, listeners will be able to: Explain an advanced role for pharmacy technicians working in cancer care through drug procurement efforts and the management of drug shortages. Provide a framework for the management of an oncology drug shortage, focusing on ensuring patient safety when implementing alternatives and solutions within your organization. Brainstorm considerations using an example of an oncology drug shortage that was recently encountered. Discuss potential future opportunities for oncology pharmacy technicians in drug procurement and leading drug shortage strategies. About the Presenter: Miranda Artiga (https://www.linkedin.com/in/miranda-vinkle-84b237139/)Miranda Artiga is a registered pharmacy technician based in Kelowna, British Columbia. She currently works at BC Cancer, where she plays a key role in supporting patient care and pharmacy operations. Miranda graduated from Stenberg College in 2018 and began her career in the retail pharmacy sector, initially working as an assistant before advancing to a pharmacy technician role. In 2022, she transitioned to BC Cancer, expanding her expertise in a specialized healthcare setting. In addition to her primary responsibilities, Miranda has served as the secondary pharmacy purchaser for the past three years, contributing to the efficient management of medication procurement and inventory. Resources Referenced: Government of Canada - Drug shortages in Canada - https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-shortages.html#a1 (https://eur02.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.canada.ca%2Fen%2Fhealth-canada%2Fservices%2Fdrugs-health-products%2Fdrug-products%2Fdrug-shortages.html%23a1&data=05%7C02%7Caidan.fay%40wearemci.com%7Cdd797fb156e1432f473e08dee653844a%7Cac144e41800148f09e1c170716ed06b6%7C0%7C0%7C639201443644265958%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=0R3DKyUD8qWI570iD6LptpWdS2pn%2BPEfEKQxiPHjiz8%3D&reserved=0) National Library of Medicine - Oncology Drug Shortages: Impacts, Policy Reforms, and Advocacy Imperatives - https://pmc.ncbi.nlm.nih.gov/articles/PMC12459138/ (https://eur02.safelinks.protection.outlook.com/?url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12459138%2F&data=05%7C02%7Caidan.fay%40wearemci.com%7Cdd797fb156e1432f473e08dee653844a%7Cac144e41800148f09e1c170716ed06b6%7C0%7C0%7C639201443644316220%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=dA54OsrveBXVqFuAqXMAJ2QR4%2FVLPWsxGiSKL6VzrbA%3D&reserved=0) USP - Why cancer medicines are and continue to be vulnerable to drug shortages - https://qualitymatters.usp.org/why-cancer-medicines-are-and-continue-be-vulnerable-drug-shortages (https://eur02.safelinks.protection.outlook.com/?url=https%3A%2F%2Fqualitymatters.usp.org%2Fwhy-cancer-medicines-are-and-continue-be-vulnerable-drug-shortages&data=05%7C02%7Caidan.fay%40wearemci.com%7Cdd797fb156e1432f473e08dee653844a%7Cac144e41800148f09e1c170716ed06b6%7C0%7C0%7C639201443644341443%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=yq9Lac%2FoRQHSFY4PsCMFCFDn9JskXzOBktVeG4%2Frizo%3D&reserved=0) Government of Canada - Annex 1 to the Good manufacturing practices guide – Manufacture of sterile drugs (GUI-0119): Premises, equipment, utilities and personnel - https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/good-manufacturing-practices/guidance-documents/gmp-guidelines-annex-1-manufacture-sterile-drugs-0119/premises-equipment.html (https://eur02.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.canada.ca%2Fen%2Fhealth-canada%2Fservices%2Fdrugs-health-products%2Fcompliance-enforcement%2Fgood-manufacturing-practices%2Fguidance-documents%2Fgmp-guidelines-annex-1-manufacture-sterile-drugs-0119%2Fpremises-equipment.html&data=05%7C02%7Caidan.fay%40wearemci.com%7Cdd797fb156e1432f473e08dee653844a%7Cac144e41800148f09e1c170716ed06b6%7C0%7C0%7C639201443644365977%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=bVFM0ndCLwp47cv9gwmpc%2Bql7wmgv%2BQP8%2FWPTvZdkwM%3D&reserved=0) Government of Canada - Tier 3 Drug Shortages - https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-shortages/tier-3-shortages.html#wb-auto-4 (https://eur02.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.canada.ca%2Fen%2Fhealth-canada%2Fservices%2Fdrugs-health-products%2Fdrug-products%2Fdrug-shortages%2Ftier-3-shortages.html%23wb-auto-4&data=05%7C02%7Caidan.fay%40wearemci.com%7Cdd797fb156e1432f473e08dee653844a%7Cac144e41800148f09e1c170716ed06b6%7C0%7C0%7C639201443644390672%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=KKY9882%2BoDfgb2yxSpTZ7sAWj5N%2BYtooFZm3gZue9U4%3D&reserved=0) Government of Canada - List of drugs for exceptional importation and sale - https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-shortages/list.html#wb-auto (https://eur02.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.canada.ca%2Fen%2Fhealth-canada%2Fservices%2Fdrugs-health-products%2Fdrug-products%2Fdrug-shortages%2Flist.html%23wb-auto&data=05%7C02%7Caidan.fay%40wearemci.com%7Cdd797fb156e1432f473e08dee653844a%7Cac144e41800148f09e1c170716ed06b6%7C0%7C0%7C639201443644418316%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=zFLFudtxMLCggv7BXqUjQb9DqKvhJtteOY%2BWXpPdfKI%3D&reserved=0) Government of Canada - Draft Guidance Document: Generic Drug Equivalence: Medicinal Ingredients - https://www.canada.ca/en/health-canada/services/drugs-health-products/public-involvement-consultations/drug-products/consultation-profile-draft-generic-drug-equivalence/document-1.html (https://eur02.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.canada.ca%2Fen%2Fhealth-canada%2Fservices%2Fdrugs-health-products%2Fpublic-involvement-consultations%2Fdrug-products%2Fconsultation-profile-draft-generic-drug-equivalence%2Fdocument-1.html&data=05%7C02%7Caidan.fay%40wearemci.com%7Cdd797fb156e1432f473e08dee653844a%7Cac144e41800148f09e1c170716ed06b6%7C0%7C0%7C639201443644458393%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=%2BiT8VUNeE%2BDczafDeCGiM5eLGNXkrwKNN5BwmNvV0OU%3D&reserved=0) Health Product Shortages Canada - https://healthproductshortages.ca/ (https://eur02.safelinks.protection.outlook.com/?url=https%3A%2F%2Fhealthproductshortages.ca%2F&data=05%7C02%7Caidan.fay%40wearemci.com%7C87186f99b23349bffd1a08dee7616e7d%7Cac144e41800148f09e1c170716ed06b6%7C0%7C0%7C639202602841749040%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=HUsKC3vPOE%2FiP5iwdfdUUFGLxsORjpts5WDuw2uZVLI%3D&reserved=0).

Reach and audience

Public platform figures. Ratings count people who left a rating, not total listeners.

Spotify

4.7 / 5

3 ratings

Podcast Authority Score: 21 / 100

A composite of feed quality, social presence, YouTube performance and engagement. Read the methodology.

Quality

15

Social presence

0

YouTube

0

Engagement

68